Show simple item record

dc.contributor.authorPalacios, Natalia
dc.contributor.authorHannoun, Anas
dc.contributor.authorFlahive, Julie
dc.contributor.authorWard, Doyle V.
dc.contributor.authorGoostrey, Kelsey
dc.contributor.authorDeb, Anindita
dc.contributor.authorSmith, Kara M
dc.date2022-08-11T08:09:59.000
dc.date.accessioned2022-08-23T16:51:20Z
dc.date.available2022-08-23T16:51:20Z
dc.date.issued2021-03-04
dc.date.submitted2021-06-14
dc.identifier.citation<p>Palacios N, Hannoun A, Flahive J, Ward D, Goostrey K, Deb A, Smith KM. Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease. Front Neurol. 2021 Mar 4;12:574529. doi: 10.3389/fneur.2021.574529. PMID: 33746867; PMCID: PMC7970035. <a href="https://doi.org/10.3389/fneur.2021.574529">Link to article on publisher's site</a></p>
dc.identifier.issn1664-2295 (Linking)
dc.identifier.doi10.3389/fneur.2021.574529
dc.identifier.pmid33746867
dc.identifier.urihttp://hdl.handle.net/20.500.14038/41837
dc.description.abstractBackground: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed. Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of 19 PD patients who had not previously been exposed to Levodopa. Patients provided two stool samples prior to and two samples 90 days after starting Levodopa. Motor impairment (MDS-UPDRS Part III), diet, and other patient characteristics were assessed. 16S rRNA gene amplicon sequencing was used to characterize the microbiota. We examined, cross-sectionally and longitudinally, the associations between Levodopa use and alpha and beta diversity and performed feature-wise, multivariate modeling to identify taxa associated longitudinally with Levodopa use and with improvement in motor function after Levodopa administration. Results: We did not observe significant differences in alpha or beta diversity before vs. after initiation of Levodopa. In longitudinal feature-wise analyses, at the genus level, no taxa were significantly associated with Levodopa use after false discovery rate (FDR) correction (q < 0.05). We observed a marginally lower relative abundance of bacteria belonging to Clostridium group IV in PD patients who experienced a medium or large improvement in motor impairment in response to Levodopa compared to those with a small response [beta = -0.64 (SE: 0.18), p-trend: 0.00015 p-FDR: 0.019]. Conclusions: In this study, Levodopa was not associated with changes in microbiota composition in this longitudinal analysis. The association between abundance of Clostridium group IV and short-term motor symptom response to Levodopa is preliminary and should be investigated in larger, longer-term studies, that include a control group.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=33746867&dopt=Abstract">Link to Article in PubMed</a></p>
dc.rightsCopyright © 2021 Palacios, Hannoun, Flahive, Ward, Goostrey, Deb and Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectLevodopa
dc.subjectParkinson's disease
dc.subjectUnified Parkinson's Disease Rating Scale
dc.subjectmicrobiome
dc.subjectmotor function
dc.subjectAmino Acids, Peptides, and Proteins
dc.subjectDigestive System
dc.subjectMicrobiology
dc.subjectMusculoskeletal, Neural, and Ocular Physiology
dc.subjectNervous System Diseases
dc.subjectNeurology
dc.subjectNeuroscience and Neurobiology
dc.titleEffect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
dc.typeJournal Article
dc.source.journaltitleFrontiers in neurology
dc.source.volume12
dc.identifier.legacyfulltexthttps://escholarship.umassmed.edu/cgi/viewcontent.cgi?article=5669&amp;context=oapubs&amp;unstamped=1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/oapubs/4638
dc.identifier.contextkey23344509
refterms.dateFOA2022-08-23T16:51:20Z
html.description.abstract<p>Background: The impact of Levodopa on the gut microbiota of Parkinson's disease (PD) patients has not been sufficiently addressed.</p> <p>Methods: We conducted a longitudinal study to examine the impact of Levodopa initiation on the gut microbiota composition of 19 PD patients who had not previously been exposed to Levodopa. Patients provided two stool samples prior to and two samples 90 days after starting Levodopa. Motor impairment (MDS-UPDRS Part III), diet, and other patient characteristics were assessed. 16S rRNA gene amplicon sequencing was used to characterize the microbiota. We examined, cross-sectionally and longitudinally, the associations between Levodopa use and alpha and beta diversity and performed feature-wise, multivariate modeling to identify taxa associated longitudinally with Levodopa use and with improvement in motor function after Levodopa administration.</p> <p>Results: We did not observe significant differences in alpha or beta diversity before vs. after initiation of Levodopa. In longitudinal feature-wise analyses, at the genus level, no taxa were significantly associated with Levodopa use after false discovery rate (FDR) correction (q < 0.05). We observed a marginally lower relative abundance of bacteria belonging to Clostridium group IV in PD patients who experienced a medium or large improvement in motor impairment in response to Levodopa compared to those with a small response [beta = -0.64 (SE: 0.18), p-trend: 0.00015 p-FDR: 0.019].</p> <p>Conclusions: In this study, Levodopa was not associated with changes in microbiota composition in this longitudinal analysis. The association between abundance of Clostridium group IV and short-term motor symptom response to Levodopa is preliminary and should be investigated in larger, longer-term studies, that include a control group.</p>
dc.identifier.submissionpathoapubs/4638
dc.contributor.departmentDepartment of Neurology
dc.contributor.departmentUMass Center for Microbiome Research
dc.contributor.departmentDepartment of Microbiology and Physiological Systems
dc.contributor.departmentDepartment of Population and Quantitative Health Sciences
dc.source.pages574529


Files in this item

Thumbnail
Name:
fneur_12_574529.pdf
Size:
894.0Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Copyright © 2021 Palacios, Hannoun, Flahive, Ward, Goostrey, Deb and Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Except where otherwise noted, this item's license is described as Copyright © 2021 Palacios, Hannoun, Flahive, Ward, Goostrey, Deb and Smith. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.